Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide prevention of camrelizumab-related adverse reactions in advanced non-small cell lung cancer
ChiCTR2400087229Phase 4Not yet recruiting
- Sponsor
- Huai'an First People's Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thalidomide in non-small cell lung cancer (NSCLC), sponsored by Huai'an First People's Hospital. Primary endpoint: Incidence of treatment-related adverse events. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400087229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087229.